Latest news with #SI-BONE
Malaysian Reserve
5 days ago
- Business
- Malaysian Reserve
Synergy Spine Solutions Appoints Troy Wahlenmaier as Chief Commercial Officer
LOUISVILLE, Colo., Aug. 14, 2025 /PRNewswire/ — Synergy Spine Solutions Inc., a leading innovator in artificial cervical disc replacement, today announced the appointment of Troy Wahlenmaier as Chief Commercial Officer (CCO). In this role, Mr. Wahlenmaier will lead global sales and marketing efforts as the company accelerates its growth and prepares for U.S. commercialization. With more than 30 years of commercial leadership in the medical device industry, Mr. Wahlenmaier brings deep expertise in scaling high-performance sales organizations, executing successful commercialization strategies, and driving sustained revenue growth. Mr. Wahlenmaier joins Synergy following a distinguished 13-year tenure at SI-BONE, where he served as Senior Vice President of U.S. Sales. Under his leadership, SI-BONE's U.S. revenue grew an average of 20% annually, reaching a projected $188 million in 2025. He built and led a commercial team of over 200 professionals and a robust distributor network, while also playing a key role in delivering SI-BONE's first quarter of positive Adjusted EBITDA and cash flow breakeven – marking a major milestone in the company's commercial evolution. 'Troy brings a proven track record of commercial success in innovative spinal implants and medical technologies,' said Josh Butters, Chief Executive Officer of Synergy Spine Solutions. 'He's a visionary leader with a rare blend of strategic focus and people-first leadership. His ability to build scalable, culture-driven commercial teams will be pivotal as we accelerate growth and prepare for U.S. market entry.' Throughout his career, Mr. Wahlenmaier has held leadership roles at top medical device companies including NuVasive, Kyphon, SpineTech, and United States Surgical Corporation. He has consistently exceeded revenue targets by developing market-leading teams and navigating the complexities of both private and public company environments. His experience spans early-stage commercialization, market development, and operational execution. 'I'm thrilled to join Synergy Spine Solutions at such a pivotal and transformative time,' said Mr. Wahlenmaier. 'The company's commitment to innovation and improving patient outcomes aligns perfectly with my passion for building high-impact commercial teams. I look forward to working with the entire Synergy team to expand our market presence and deliver sustained value to our customers, partners, and shareholders.' Mr. Wahlenmaier holds a Bachelor of Business Administration from Wichita State University and resides in Colorado. About Synergy Spine Solutions The Vision of Synergy Spine Solutions is to identify and commercialize innovative spine technologies that help surgeons improve their patients' quality of life and advance the standard of care. The company's flagship product, the Synergy Disc®, is the only device that is designed to restore both motion and alignment to the spine. For media inquiries, please contact:Tim HeinVP of Sales and Marketingtimhein@ +1 360 991 6300https:// Logo – View original content:
Yahoo
05-08-2025
- Business
- Yahoo
SI-BONE Inc (SIBN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Positive ...
Worldwide Revenue: $48.6 million, growth of 21.7%. US Revenue: $46.4 million, growth of 22.8%. International Revenue: $2.2 million. Gross Profit: $38.8 million, increase of $7.2 million. Gross Margin: 79.8%, expanded by 80 basis points year-over-year. Operating Expenses: $45.8 million, increase of $4.2 million. Net Loss: $6.2 million or $0.14 per diluted share. Adjusted EBITDA: Positive $1 million, compared to a loss of $2.7 million in the prior year. Cash and Marketable Securities: $145.5 million, up from $144.4 million. Full Year Revenue Guidance: $195 million to $198 million, growth of approximately 17% to 18%. Full Year Gross Margin Guidance: 78.5% to 79%. Warning! GuruFocus has detected 3 Warning Signs with SIBN. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points SI-BONE Inc (NASDAQ:SIBN) reported a worldwide revenue growth of approximately 22% for the second quarter of 2025, with US revenue growing by 23%. The company achieved cash flow break-even ahead of schedule, marking a significant financial milestone. SI-BONE Inc (NASDAQ:SIBN) experienced a 25% increase in US procedure volumes, indicating strong demand across its target markets. The launch of iFuse TORQ in Europe is expected to accelerate adoption and growth in international markets. The company delivered its third consecutive quarter of positive adjusted EBITDA, demonstrating consistent profitability. Negative Points International revenue growth was impacted by a later-than-expected regulatory clearance for iFuse TORQ in Europe. The average procedure ASP declined slightly, although it remained more stable than initially expected. There is an anticipated sequential revenue decline of approximately 4% in Q3 due to seasonality and certifications. Gross margins are expected to be dynamic over the next few years, with potential compression due to new product launches and associated costs. The company faces ongoing pricing pressure, with an assumed 2% ASP decline in the second half of the year. Q & A Highlights Q: Can you discuss the assumptions underlying the revenue growth guidance for the second half of 2025, given the strong growth in the first half? A: Laura Francis, CEO: We are pleased with the 23% US growth and the acceleration between Q1 and Q2. Our strategy is working, and we are growing towards profitability. We achieved cash flow breakeven earlier than expected. Anshul Maheshwari, CFO, added that while there are tailwinds like Granite adoption and TNT capacity, they are maintaining a prudent approach to guidance, expecting a sequential decline in Q3 due to seasonality, with a ramp in Q4. Q: How should we think about gross margin guidance, given the strong performance in the first half of 2025? A: Anshul Maheshwari, CFO: We started the year expecting 77% to 78% gross margins, but have outperformed. We are now guiding 78.5% to 79% for the year. We are embedding some ASP pressure and costs from new product launches, but there is potential for better-than-anticipated ASP and additional margin improvement initiatives. Q: Can you provide more color on the growth of interventional docs using your products and their impact? A: Laura Francis, CEO: Interventional docs have been a strong growth driver since we started working with them over a year ago. TORQ is the product of choice, but many also use our INTRA product where reimbursement is defined. Interventionalists are often in areas where surgeons are not performing these procedures, providing a nice balance. Q: What is the potential for Granite procedures to move to outpatient settings, and how does this impact your business? A: Laura Francis, CEO: CMS has proposed allowing higher-cost lumbar fusion procedures in outpatient settings, which could increase Granite's use in these settings. Granite's transitional pass-through code and $0 device offset could drive more procedures to outpatient settings, especially short construct degenerative spine procedures. Q: How are you prioritizing capital deployment given your cash flow breakeven achievement? A: Anshul Maheshwari, CFO: We expect revenue growth to outpace OpEx growth, with continued investments in R&D and sales force expansion. We aim for 10% of revenue in R&D, with sales and marketing growth aligned with revenue growth. We have the liquidity to invest in organic growth initiatives. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-06-2025
- Business
- Yahoo
SI-BONE to Truist Securities MedTech Conference on June 17, 2025
SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 17, 2025, at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: Truist Securities MedTech Conference. Live audio of the webcast will be available on the 'Investors' section of the company's website at: The webcast will be archived and available for replay for at least 90 days after the event. About SI-BONE, Inc. SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,500 physicians in performing a total of over 120,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies with over 160 peer reviewed publications including two randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma. For additional information on the company or the products, including risks and benefits, please visit SI-BONE, Sacropelvic Solutions, iFuse Implant System®, iFuse Bedrock Granite, and iFuse TORQ, are registered trademarks, and iFuse 3D, iFuse TORQ TNT, and iFuse INTRA are trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved. Investor Contact: Saqib Iqbal, investors@ in to access your portfolio
Yahoo
06-05-2025
- Business
- Yahoo
SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025
SI-BONE, Inc. SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: Live audio of the webcast will be available on the 'Investors' section of the company's website at: The webcast will be archived and available for replay for at least 90 days after the event. About SI-BONE, Inc. SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 4,500 physicians in performing a total of over 120,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including two randomized controlled trials and over 160 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma. For additional information on the company or the products including risks and benefits, please visit iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, SI-BONE, and iFuse INTRA are registered trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved. Investor Contact: Saqib Iqbal investors@
Yahoo
25-02-2025
- Business
- Yahoo
SI-BONE Inc (SIBN) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Positive EBITDA
Worldwide Revenue: $49 million in Q4 2024, growth exceeding 26%. US Revenue: $46.9 million in Q4 2024, 28% growth. International Revenue: $2.1 million in Q4 2024. Full Year 2024 Revenue: $167.2 million, over 20% growth. Gross Profit: $38.8 million in Q4 2024, 35% increase. Gross Margin: 79% for both Q4 and full year 2024. Operating Expenses: $44.3 million in Q4 2024, 8% growth. Net Loss: $4.5 million in Q4 2024, improved by nearly 60%. Adjusted EBITDA: $1.9 million in Q4 2024, compared to a loss of $4.8 million in Q4 2023. Cash and Marketable Securities: $150 million at the end of 2024. 2025 Revenue Guidance: $193.5 million to $195.5 million, 16% to 17% growth. 2025 Gross Margin Guidance: Expected between 77% and 78%. Warning! GuruFocus has detected 7 Warning Signs with SIBN. Release Date: February 24, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. SI-BONE Inc (NASDAQ:SIBN) reported a record $49 million in worldwide revenue for Q4 2024, representing over 26% growth. U.S. revenue increased by 28% to $46.9 million, driven by strong demand from nearly 1,400 active physicians. The company achieved positive adjusted EBITDA in Q4 2024 and expects to maintain this for the full year 2025. SI-BONE Inc (NASDAQ:SIBN) has successfully launched new products like Granite 9.5 and TNT, which have exceeded adoption expectations. The company has a strong liquidity position with $150 million in cash and marketable securities, and is focused on achieving positive free cash flow. SI-BONE Inc (NASDAQ:SIBN) faces risks related to maintaining favorable reimbursement for its products and procedures. There is potential economic weakness that could impact patients' ability and desire to undergo elective procedures. The company is involved in an ongoing DOJ investigation, which could pose legal and reputational risks. Guidance for 2025 revenue growth is slightly lower at 16% to 17%, compared to previous years' higher growth rates. Gross margins are expected to decline slightly in 2025 due to factors like procedure mix and increased depreciation. Q: Can you discuss the growth drivers for SI-BONE in 2024 and expectations for 2025? A: Laura Francis, CEO, highlighted that the growth in 2024 was driven by strong demand across all procedure types and call points, including SI joint fusion, Granite 9.5, and TNT. The company expects these growth drivers to strengthen in 2025 due to product launches in 2024, positioning SI-BONE for continued top-tier med tech revenue growth. Q: Why is the 2025 revenue growth guidance of 16% to 17% lower than previous years? A: Anshul Maheshwari, CFO, explained that while the company is optimistic about 2025, they have taken a balanced approach to guidance. Factors such as potential reimbursement tailwinds, procedure mix impacts on ASP, and one less procedure day have been considered. The company remains confident in capitalizing on demand throughout the year. Q: How is SI-BONE positioned in the competitive landscape, particularly with potential disruptions in the spine market? A: Laura Francis, CEO, stated that SI-BONE remains the market leader in SI joint fusion, supported by a comprehensive product portfolio and strong educational and advocacy infrastructure. The company continues to compete effectively and sees its recent product launches as a foundation for future growth. Q: What are the expectations for gross margins in 2025, and how do they compare to previous years? A: Anshul Maheshwari, CFO, noted that the expected gross margin for 2025 is 77% to 78%, slightly lower than 2024 due to factors like ASP impacts from procedure mix and increased depreciation from new surgical capacity. However, the company is working on initiatives to offset these pressures and maintain strong margins. Q: Can you provide an update on the DOJ investigation and any changes to company practices? A: Laura Francis, CEO, mentioned that SI-BONE is cooperating with the DOJ transparently and has a strong compliance program in place. The investigation focuses on field-based education events and physician remuneration. The company will update investors as material information becomes available. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
